TDG Inhibitors

TDG inhibitors encompass a wide spectrum of compounds that exhibit the capacity to hinder TDG activity through either direct or indirect mechanisms, ultimately contributing to the modulation of specific cellular pathways and processes. Direct inhibitors, including 5-Aza-2'-deoxycytidine, RG108, and Zebularine, exert their inhibitory effects by directly interfering with TDG's enzymatic activity. By doing so, they effectively impede the removal of 5-methylcytosine and DNA demethylation processes, effectively curbing TDG's epigenetic functions.

In contrast, indirect inhibitors like 5-Fluorouracil, Oxaliplatin, and Methotrexate disrupt TDG activity indirectly by inducing DNA damage or interfering with nucleotide availability. These actions result in a reduction of TDG's involvement in DNA repair processes, further exacerbating its inhibitory impact. Moreover, compounds such as 6-Thioguanine, 8-Oxoguanine, and DZNep function as indirect inhibitors by perturbing normal DNA repair pathways or modifying histone methylation patterns, thus inducing changes in TDG function. Additionally, aminoglycoside antibiotics and 2-Methoxyestradiol indirectly hinder TDG by disrupting its DNA binding or affecting its cellular localization. In unison, these diverse mechanisms employed by TDG inhibitors underscore their collective ability to influence various cellular processes and pathways, all of which contribute to the inhibition of TDG's pivotal role in DNA repair.